The global Biomodex business reached a total turnover of EUR 2.2 million in 2022.
Biomodex specializes in biorealistic 3D printing and flow systems for interventional procedures, with a platform geared towards clinical use and patient-specific simulation. As part of the acquisition, Mentice will also retain key employees of Biomodex.
“Biomodex is truly a quality product company, with experienced staff and a large and highly engaged customer base which is a testament to the value they bring to the market,” says Edward Fält, Chief Strategy Officer of Mentice. “Since its inception in 2015, Biomodex has invested over 12 million EUR in IP and R&D, leading to the development of several innovative products and technology advances which will be very synergistic to Mentice’s current portfolio. Thanks to a series of circumstances, we were able to acquire these assets under favorable terms and are now looking forward to taking the business to the next level under the umbrella of the global Mentice organization.”
The acquired assets will add new solutions for neurovascular and structural heart simulation as well as a rapid turn-around production process for direct printing of patient-specific anatomies. Over the course of 2024, Mentice aims to focus on integrating the Biomodex staff, product lines and production into its existing business areas, it states.
Photo: iStock
